Characteristics of Patients with BMT Nephropathy at Diagnosis
| Characteristic | Unique patient number | |||||
|---|---|---|---|---|---|---|
| 664 | 717 | 737 | 788 | 806 | 876 | |
| Age (y) | 33 | 47 | 25 | 33 | 32 | 45 |
| Sex | F | M | F | F | M | F |
| Diagnosis | Acute myelogenous leukemia | Myelodysplastic syndrome | Chronic myelogenous leukemia | Acute myelogenous leukemia | Chronic myelogenous leukemia | Acute myelogenous leukemia |
| Donor | Haploidentical sibling | Sibling | Haploidentical sibling | Matched family donor | 1-mismatch matched family donor | Matched family donor |
| Stem cell source | Peripheral blood | Peripheral blood | Peripheral blood | Peripheral blood | Peripheral blood | Bone marrow |
| Conditioning | TBI, cyclophosphamide, thiotepa | TBI, cyclophosphamide | TBI, cyclophosphamide, thiotepa | TBI, cyclophosphamide | TBI, cyclophosphamide | Busulfan, cyclophosphamide |
| Radioimmunotherapy source | 188Re | 188Re | 188Re | 188Re | 188Re | 188Re |
| Graft-vs.-host disease | Acute, grade 1 | None | None | Acute, grade 2 | Chronic | None |
| Cyclosporine use | None | None | None | None | None | Yes* |
| Bone marrow dose (Gy) | 16 | 11 | 10 | 20 | 18 | 21 |
| Kidney dose (Gy) | 5 | 8 | 2 | 9 | 6 | 12 |
| Hypertension | + | + | + | + | + | − |
| Hemoglobin (g/dL) | 10.2 | 10.2 | 8.7 | 9 | 6.8 | 6.2 |
| Lactate dehydrogenase (U/L) (normal, <250) | Not done | 285 | 519 | 157 | 329 | 324 |
| Schistocytes | Not done | + | + | − | + | + |
| Erythropoietin level (U/L) (normal, 3.3–16) | Not done | Not done | 32.2 | 1.7 | 110.4 | 32.6 |
| Hematuria | − | + | + | +++ | + | +++ |
| Proteinuria (mg/L) | + | 1,024 | 3,144 | 554 | 234 | 1,130 |
| Platelet count | 106 | 96 | 61 | 92 | 106 | 73 |
↵* Discontinued 5 mo before onset of BMT nephropathy.
TBI = 12 Gy; cyclophosphamide = 120 mg/kg; busulfan = 12.8 mg/kg.